Key Decisions in HIV Care #1: Optimizing Switch Strategies for Patients With Viral Suppression

In this live, 45-minute Webinar, expert faculty review key considerations when selecting a new ART regimen for patients with viral suppression who need a change in HIV treatment. Topics will include weighing the pros and cons of switching to contemporary 3-drug therapy regimens, oral 2-drug options, and long-acting injectable 2-drug regimens. Following a didactic presentation, faculty will answer your most pressing questions on switching ART in virologically suppressed patients.

Following registration, submit your questions in advance!

Agenda

Key data and guidance on switching ART in patients with viral suppression (30 minutes)

Attendee questions answered by the experts (15 minutes)

Events

Date / Time
Event Details

Faculty

Faculty
Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Faculty
Chloe Orkin, MBChB, FRCP, MD

Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom

Goal Statement
The goal of this activity is to provide sustained education that will improve clinicians’ knowledge and competence in making key decision points in HIV care that are focused on the needs of their individual patients.

Target Audience
This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for persons with HIV.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess individual patient factors and regimen options when determining whether and how to modify therapy in virologically suppressed individuals

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. UAN: JA4008176-0000-21-099-L02-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.